Skip to content

Randomized Study of Letrozole and Trilostane for Medical Abortion

A Randomized Pilot Study of Two New Drug Combinations Fot the Termination fo Early Pregnancy

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01615211
Enrollment
36
Registered
2012-06-08
Start date
2012-05-31
Completion date
2013-10-31
Last updated
2015-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medical Abortion, Complete or Unspecified, Without Complication

Keywords

Abortion, medical abortion, termination of pregnancy, Mifepristone, misoprostol, letrozole, trilostane, femara, Modrenal

Brief summary

In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and estrogen levels fall sharply at this time. During medical abortion the endometrial shedding is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or require surgical intervention. In medical abortion a progesterone antagonist is used as treatment but the estrogen levels are not targeted. The investigators wish to explore whether addition of letrozole or trilostane which target estrogen levels can lead to a more effective shedding of the endometrial lining.

Interventions

DRUGLetrozole

Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets

Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice

Sponsors

Karolinska Institutet
CollaboratorOTHER
The University of Hong Kong
CollaboratorOTHER
Kristina Gemzell Danielsson
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Healthy women aged 18-45 without any contraindication for treatment of any of the drugs involved in teh study

Exclusion criteria

* Any ongoing medication or medical condition smoking \>20 cigarettes per day BMI \>30

Design outcomes

Primary

MeasureTime frameDescription
efficacy4 weeksEvaluation of complete abortion by clinical judgement and ultrasonography

Secondary

MeasureTime frameDescription
Acceptability1 week, 2 weeks and 4 weeksquestionnaire. Preferred future method of medical abortion.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026